Daniel Bowles, MD
Medical Oncology · Aurora, CONPI 1720134315
Payments from drug & device makers
Across 579 payments — averaging $3815.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$784K
- Pfizer$384K
- Hoffmann-la Roche Limited$178K
- Genentech, Inc.$157K
- Astellas Pharma Global Development$150K
- Blueprint Medicines Corporation$143K
- plus $412K from 15 others
Across 2 payments — averaging $668.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$940
- F. Hoffmann-la Roche AG$397
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 179 | $783,848 |
| Pfizer | 40 | $384,384 |
| Hoffmann-la Roche Limited | 24 | $177,657 |
| Genentech, Inc. | 110 | $157,443 |
| Astellas Pharma Global Development | 19 | $150,320 |
| Blueprint Medicines Corporation | 15 | $143,492 |
| Bayer | 94 | $109,218 |
| Sumitomo Pharma America, Inc. | 10 | $60,410 |
| AstraZeneca | 3 | $33,513 |
| AVEO Pharmaceuticals, Inc. | 17 | $30,820 |
| E.r. Squibb & Sons, L.L.C. | 4 | $28,956 |
| Janssen Research & Development, LLC | 21 | $28,009 |
| Merck | 13 | $26,687 |
| AbbVie | 3 | $24,100 |
| Regeneron | 8 | $22,722 |
| Novartis | 5 | $18,565 |
| Bristol Myers Squibb | 7 | $12,628 |
| Macrogenics, Inc. | 1 | $9,500 |
| F. Hoffmann-la Roche AG | 4 | $4,608 |
| Eisai Inc. | 1 | $1,963 |
| Zimmer Biomet | 1 | $149 |
How this compares
$2,208,991 in reported general payments places this provider in the 80th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Aurora
- Karl LewisAurora$12.4M
- Christopher LieuAurora$8M
- David CamidgeAurora$7.3M
- Theresa MedinaAurora$7M
- Wells MessersmithAurora$6.3M
- Antonio JimenoAurora$5.6M
- Elizabeth KesslerAurora$5.1M
- Sarah DavisAurora$3.9M
- Sunnie KimAurora$3.9M
- Peter KabosAurora$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.